Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study-Reference-Cited by-同舟云学术

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Published:2019-04-22 Issue:5 Volume:25 Page:738-743
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Rothwell Dominic G.,Ayub Mahmood,Cook Natalie,Thistlethwaite Fiona,Carter Louise,Dean Emma^ORCID,Smith Nigel,Villa Shaun,Dransfield Joanne,Clipson Alexandra,White Daniel,Nessa Kamrun,Ferdous Saba^ORCID,Howell Matthew,Gupta Avinash,Kilerci Bedirhan,Mohan Sumitra,Frese Kris,Gulati Sakshi,Miller Crispin,Jordan Allan,Eaton Helen,Hickson Nicholas,O’Brien Ciara,Graham Donna,Kelly Claire,Aruketty Sreeja,Metcalf Robert,Chiramel Jaseela,Tinsley Nadina,Vickers Alexander J.,Kurup Roopa,Frost Hannah,Stevenson Julie,Southam Siobhan,Landers Dónal,Wallace Andrew,Marais Richard^ORCID,Hughes Andrew M.,Brady Ged,Dive Caroline^ORCID,Krebs Matthew G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-019-0380-z.pdf

Reference27 articles.

1. Schwaederle, M. et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2, 1452–1459 (2016).

2. Schwaederle, M. et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J. Clin. Oncol. 33, 3817–3825 (2015).

3. Jänne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689–1699 (2015).

4. Shaw, A. T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189–1197 (2014).

5. Drilon, A. et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400–409 (2017).

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid biopsy for monitoring minimal residual disease in colorectal cancer: A promising approach with clinical implications;Clinical Surgical Oncology;2024-09

2. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer;British Journal of Cancer;2024-08-28

3. CRISPR/Cas12a cleavage triggered nanoflower for fluorescence-free and target amplification-free biosensing of ctDNA in the terahertz frequencies;Biomedical Optics Express;2024-08-21

4. Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers;International Journal of Molecular Sciences;2024-08-09

5. Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy;BMC Cancer;2024-07-28